black box warning for glp 1 agonists Tirzepatide injection (Zepbound®): Basic information prescribers Black Box Warnings for Medications:

2015;5(6):e583

Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

Adverse effects included: Severe hypoglycaemia , acute pancreatitis and gastrointestinal side effects

Medical science has made such tremendous progress that there is hardly a healthy human left. Aldous Huxley GLP-1 Agonists at a Glance First-Generation (Short-Acting) Exenatide Byetta Lixisenatide Adlyxin / Lyxumia Second-Generation (Long-Acting) Exenatide ER Bydureon (weekly, now discontinued in some markets) Liraglutide Victoza (diabetes), Saxenda (obesity) Dulaglutide Trulicity Semaglutide Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) Dual Agonist (GIP + GLP-1) Tirzepatide Mounjaro (diabetes), Zepbound (obesity) Triple or Combination Agonists (In Development) Retatrutide Triple agonist (GLP-1 + GIP + glucagon) CagriSema Combination of cagrilintide + semaglutide (GLP-1 + amylin analog) Orforglipron Oral, non-peptide GLP-1 receptor agonist (Eli Lilly) Danuglipron Oral small-molecule GLP-1 agonist (Pfizer) Efinopegdutide GLP-1/glucagon dual agonist (Merck/Biocon) AMG133 GLP-1 + GIP receptor modulator (Amgen)

Although there is strong evidence supporting the benefit of GLP-1RAs in populations with obesity, their efficacy in other populations of particular HF subtypes and specific cardiomyopathies is unclear

J.BhattD